Australia Molecular Diagnostics Market

Australia Molecular Diagnostics Market Overview:

The Australia molecular diagnostics market size reached USD 585.20 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1140.46 Million by 2033, exhibiting a growth rate (CAGR) of 6.90% during 2025-2033. Personalized medicine adoption, expanded genomic testing programs, and growing demand for early disease detection are reshaping diagnostic needs. Regulatory fast-tracking, infrastructure upgrades, automation, and the considerable rise in the number of decentralized molecular platforms are enhancing diagnostic accessibility. Public-private partnerships, point-of-care innovations, and genomic integration are some of the factors positively impacting the Australia molecular diagnostics market share.

Australia Molecular Diagnostics Market Trends:

Rising Demand for Personalized Medicine and Early Disease Detection

Australia's healthcare system has witnessed a strategic shift toward precision medicine, particularly within oncology, infectious diseases, and rare genetic disorders. This transition is underpinned by growing investments in genomic research and national initiatives such as the Genomics Health Futures Mission, which allocates public funding for translational research and clinical application of molecular diagnostics. Hospitals and diagnostic laboratories are increasingly adopting PCR-based, NGS, and microarray platforms to deliver faster, more targeted testing capabilities. On February 24, 2025, Immunexpress, headquartered in Seattle and Brisbane, presented new data at the SCCM 2025 Congress in Orlando on its SeptiCyte® RAPID test, which rapidly differentiates sepsis from non-infectious inflammation using host gene expression. The test, now approved by Australia’s Therapeutic Goods Administration (TGA), supports faster clinical decisions in managing over 90,000 annual sepsis cases in Australia, which carry an estimated AUD 700 million (USD 460 million) in direct and AUD 4 billion (USD 2.6 billion) in total costs. SeptiCyte RAPID is validated across diverse patient groups and enhances early intervention, antibiotic stewardship, and healthcare efficiency. This is particularly important in oncology, where molecular testing informs therapeutic decisions and predicts drug response.

The growing need for early and accurate disease detection also fuels demand, especially in managing outbreaks of respiratory illnesses, sexually transmitted infections, and antimicrobial resistance. Molecular assays offer higher specificity and sensitivity compared to traditional diagnostic techniques, allowing for better patient stratification and timely intervention. In addition, public-private collaborations are facilitating the rollout of decentralised diagnostic models across regional and remote areas, addressing healthcare disparities and streamlining access to genomic testing. The expanded diagnostic reach, enabled by technological integration and public health priorities, plays a direct role in Australia molecular diagnostics market growth as healthcare providers seek to improve clinical outcomes and optimize resource allocation.

Regulatory Support and Laboratory Infrastructure Modernization

Governmental backing for diagnostic innovations has emerged as a core enabler of market expansion. Regulatory bodies such as the Therapeutic Goods Administration (TGA) have established adaptive pathways for the expedited approval of molecular tests, particularly those relevant to pandemic response, cancer care, and pharmacogenomics. This regulatory clarity has encouraged manufacturers to introduce region-specific assays and establish local manufacturing or distribution agreements. Australia’s involvement in the Asia-Pacific Economic Cooperation (APEC) Regulatory Harmonization Steering Committee has also fostered alignment with global standards, ensuring that domestic laboratories can adopt cutting-edge molecular solutions without delay. At the same time, healthcare institutions are modernizing laboratory infrastructure to accommodate high-throughput molecular workflows. The shift toward automated sample preparation, digital data management, and multiplex testing has improved both accuracy and turnaround time. Investments in regional laboratory hubs, alongside national digitization programs for health data interoperability, have enhanced diagnostic scalability.

On November 26, 2024, QIAGEN announced the inclusion of its QIAcuityDx digital PCR system in the Australian Register of Therapeutic Goods (ARTG), expanding digital PCR into clinical diagnostics across Australia and New Zealand. The system enables absolute quantitation of low-abundance DNA/RNA targets, supporting applications in oncology (e.g., liquid biopsies, BCR::ABL testing) and infectious diseases, with processing speeds as fast as 2 hours and capacity for 4 nanoplates simultaneously. With over 2,000 global placements and cited in 450+ publications, QIAcuityDx integrates imaging, thermocycling, and analysis into a single instrument, and includes IVD and Utility modes, LIMS integration, and a validated audit-ready setup. Additionally, the proliferation of point-of-care molecular platforms has reduced the diagnostic burden on centralized labs, expanding service reach to underserved populations. Collectively, these developments are shaping Australia molecular diagnostics market trends through a combination of policy alignment, automation, and decentralized testing innovation.

Australia Molecular Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on product, technology, application, and end user.

Product Insights:

• Reagents and Kits
• Instruments
• Software and Services

The report has provided a detailed breakup and analysis of the market based on the product. This includes reagents and kits, instruments, and software and services.

Technology Insights:

• Polymerase Chain Reactions (PCR)
• Hybridization
• DNA Sequencing
• Microarray
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Others

The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reactions (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others.

Application Insights:

• Infectious Diseases Diagnostics
• Oncology
• Genetic Testing
• Blood Screening
• Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes infectious diseases diagnostics, oncology, genetic testing, blood screening, and others.

End User Insights:

• Hospitals
• Laboratories
• Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, laboratories, and others.

Regional Insights:

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

The report has provided a comprehensive analysis of all major regional markets, including demand trends by component, deployment mode, enterprise size, application, and end user. This includes Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Australia Molecular Diagnostics Market News:

• On June 1, 2024, Abacus dx announced a commercial partnership with Roche to distribute its Life Science product portfolio in Australia, including advanced molecular diagnostics and tissue diagnostics technologies. The agreement covers key systems such as the LightCycler® 96, LightCycler® 480 II, MagNA Pure 24, MagNA Pure 96, and the Ventana Discovery Ultra, along with a suite of sequencing reagents. This collaboration enhances access to Roche’s molecular and tissue diagnostics solutions for Australian research institutes, academic laboratories, and biotech firms.

Australia Molecular Diagnostics Market Report Coverage:

Key Questions Answered in This Report:

• How has the Australia molecular diagnostics market performed so far and how will it perform in the coming years?
• What is the breakup of the Australia molecular diagnostics market on the basis of product?
• What is the breakup of the Australia molecular diagnostics market on the basis of technology?
• What is the breakup of the Australia molecular diagnostics market on the basis of application?
• What is the breakup of the Australia molecular diagnostics market on the basis of end user?
• What is the breakup of the Australia molecular diagnostics market on the basis of region?
• What are the various stages in the value chain of the Australia molecular diagnostics market? 
• What are the key driving factors and challenges in the Australia molecular diagnostics?
• What is the structure of the Australia molecular diagnostics market and who are the key players?
• What is the degree of competition in the Australia molecular diagnostics market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Australia molecular diagnostics market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Australia molecular diagnostics market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Australia molecular diagnostics market industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.